HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Differences in the morphine-induced inhibition of small and large intestinal transit: Involvement of central and peripheral μ-opioid receptors in mice.

Abstract
Constipation is the most common side effect of morphine. Morphine acts centrally and on peripheral sites within the enteric nervous system. There are a few comprehensive studies on morphine-induced constipation in the small and large intestine by the activation of central and peripheral μ-opioid receptors. We investigated the differences in the inhibition of the small and large intestinal transit in normal and morphine-tolerant mice. Morphine reduced the geometric center in the fluorescein isothiocyanate-dextran assay and prolonged the bead expulsion time in a dose-dependent manner. The inhibitory effects of morphine were blocked by μ-opioid antagonist β-funaltrexamine, but not by δ- and κ-opioid antagonists. The peripheral opioid receptor antagonist, naloxone methiodide, partially blocked morphine's effect in the small intestine and completely blocked its effect in the large intestine. The intracerebroventricular administration of naloxone significantly reversed the delay of small intestinal transit but did not affect morphine-induced inhibition of large intestinal transit. Naloxone methiodide completely reversed the inhibition of large intestinal transit in normal and morphine-tolerant mice. Naloxone methiodide partially reversed the morphine-induced inhibition of small intestinal transit in normal mice but completely reversed the effects of morphine in tolerant mice. Chronic treatment with morphine results in tolerance to its inhibitory effect on field-stimulated contraction in the isolated small intestine but not in the large intestine. These results suggest that peripheral and central opioid receptors are involved in morphine-induced constipation in the small and large intestine during the early stage of treatment, but the peripheral receptors mainly regulate constipation during long-term morphine treatment.
AuthorsKenjiro Matsumoto, Hiroyuki Umemoto, Tomohisa Mori, Ryuya Akatsu, Shinichiro Saito, Kimihito Tashima, Masahiro Shibasaki, Shinichi Kato, Tsutomu Suzuki, Syunji Horie
JournalEuropean journal of pharmacology (Eur J Pharmacol) Vol. 771 Pg. 220-8 (Jan 15 2016) ISSN: 1879-0712 [Electronic] Netherlands
PMID26712376 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 Elsevier B.V. All rights reserved.
Chemical References
  • Analgesics, Opioid
  • Narcotic Antagonists
  • Receptors, Opioid, mu
  • Naloxone
  • Naltrexone
  • beta-funaltrexamine
  • Morphine
Topics
  • Analgesics, Opioid (pharmacology)
  • Animals
  • Central Nervous System (drug effects)
  • Dose-Response Relationship, Drug
  • Gastrointestinal Transit (drug effects)
  • Injections, Intraventricular
  • Intestine, Large (drug effects)
  • Intestine, Small (drug effects)
  • Male
  • Mice
  • Morphine (pharmacology)
  • Naloxone (pharmacology)
  • Naltrexone (analogs & derivatives, pharmacology)
  • Narcotic Antagonists (pharmacology)
  • Peripheral Nervous System (drug effects)
  • Receptors, Opioid, mu (antagonists & inhibitors, drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: